Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Hamlet Pharma AB (publ) (7ZT.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.3290+0.0060 (+1.86%)
At close: 08:00AM CET
Advertisement

Hamlet Pharma AB (publ)

BMC D10
Klinikgatan 32
Lund 222 42
Sweden
46 40 12 25 00
https://www.hamletpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Dr. Catharina Svanborg M.D.Founder & ChairmanN/AN/A1949
Mr. Martin ErixonChief Exec. OfficerN/AN/AN/A
Mr. Mats PerssonExec. OfficerN/AN/A1961
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Hamlet Pharma AB (publ), a pharmaceutical company, engages in the development of drugs for the treatment and prevention of cancer. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company was incorporated in 1999 and is based in Lund, Sweden. Hamlet Pharma AB (publ) is a subsidiary of Linnane Pharma AB.

Corporate Governance

Hamlet Pharma AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement